Thanks Dstock for the pointers on Fluidigm that introduced mass cytrometry. Without this breakthrough validation, how the scientists could know easily the inside of the cells? Relevant biomarkers could be determined economically with this approach. You might agree that this could help Nwbo speed up its future clinical trials using biomarkers instead of OS.
Market Data 
Markets 
AI
